Newsletter sign up


ADC University Our services

ADC Review
is made possible by:



Copyright 2017
Terms & Conditions


PEER-REVIEWED ARTICLES

2nd Annual Cancer Immunotherapy Summit

Vonlanthen Group of Companies, a fast-growing multinational company that is an experienced provider of conferences, summits, exhibitions, and training programs, producing events within 6 different industries,will be hosting the 2nd Annual Cancer Immunotherapy Summit on September 21st – 22nd, 2017 in Vienna, Austria.

Following the success of the 1st Annual Cancer Immunotherapy Summit and the continued viability of immunotherapy as a cancer treatment we bring the second instalment in the series.

Immunotherapy upholds as being one of the most successful approaches to cancer treatment since the discovery of chemotherapy. To pursue this option as a feasible form of treatment, there needs to be an adequate forum for experts to share their findings and technologies. The purpose of this Summit is to bring experts, scientists, and researchers together to discuss the latest research, advancements, and developments in immunotherapy to continue the successful development of this as a form of cancer treatment.

Dr. Saso Cemerski, Principal Scientist, Merck Sharp & Dohme Ltd, USA and chairman of the event, states the importance of this topic and the need for this event: ‘Cancer treatment has moved into a new era with therapies that target the immune system showing unprecedented success in previously difficult to treat indications. While targeting negative T-cell regulators, PD-1 and CTLA-4, drove much of the initial success it also created an immediate need to identify new targets on T-cells and other immune cells present in the tumour microenvironment. Next generation targets, next generation combinations, new technologies and platforms are all critical factors that will allow improvement of the initial clinical success immuno-oncology as a field has brought to patients.

As we continue to work bringing forward from discovery into clinical development drugs that demonstrate strong preclinical proof of concept, we also continue to learn through reverse translation how to best define patient population that will respond to new therapies, how to design best biomarker plans and ultimately, design the best protocols for clinical trials. The 2nd Annual Cancer Immunotherapy Summit will surely be a great opportunity to share some of the latest research and development in the field and stimulate additional progress in the future.’

We are assembling innovators from oncology, drug development, antibody engineering, cell and gene therapy, and others for a two-day summit to espouse the latest developments in Cancer Immunotherapy research. Through a detailed outlay of the current state and future progressions in this form of treatment, attendees will be exposed to new findings. This will include:

  • The success of antibodies in therapeutics and engineering
  • The potential of the next generation immune checkpoint pathways
  • Revolutionary cancer treatments with personalized cancer vaccines
  • Reinforcing anti-tumour immunity
  • Managing unique immune-mediated adverse reactions and toxicity effects in treatment therapies
  • Progressions in genetic engineering techniques and progressions in preclinical and clinical Cancer Immunotherapy
  • Car T-cell therapy as an influence on cancer treatment
  • Regulatory aspects of the EU and the rest of the world for immunotherapy

We are excited to be hosting this critical event, as the outcome will have a lasting impact on cancer treatment therapies. Join us for what will be an engaging and insightful opportunity for those concerned with Cancer Immunotherapy development. Registration is available till September 19, 2017.


 

Antibody Drug Conjugates Summit

The Vonlanthen Group is pleased to invite you to the Antibody Drug Conjugates Summit scheduled to take place on February 25-26, 2016 in Vienna, Austria.

This innovative B2B event will enable the participants to learn about protein modeling development and engineering advances, preclinical and clinical improvements, current ADC linker chemistry- better linker design for future generations, improving preclinical and clinical translation and creating strong and scalable processes.

Key Practical Learning Points of the Summit:

  • Increase benefits of ADC- dial in potency, target stratified patient populations and optimize dosing regimens
  • Ensure product and process robustness
  • Make more evidence-based decisions
  • Explore alternative opportunities for ADCs by reviewing the potential of using ADCs outside oncology
  • Learn about advances in Protein Modeling and Engineering Breakthroughs
  • How to screen for optimal site of conjugation, select better quality targets and explore new payload mechanisms of action?
  • Linker Design Decisions, Novel Payloads and Linker Technology, Next-Generation Chemistry for Improved Conjugation and Linker Stability
  • Characterization of ADCs, Preclinical and Clinical Advances, Translational Considerations
  • Engineering ADCs for Developability, Enhanced Specificity and Binding, and Reduced Toxicity

Who Should Attend:
CEOs, Directors, Heads & Managers Of Leading Application Creators & Suppliers Including:

  • Toxicology
  • Biologics
  • Molecular Biology
  • Chief Technology Officer; Chief Development Officer; Chief Scientific Officer; Senior Research Officer
  • Biotherapeutics; Molecular Medicine; Data analysis; Analytical & Formulation
  • Oncology Drug Development; Oncology Molecules
  • Medical information
  • Bioanalytical
  • Discovery Chemistry; Research & Development; Antibody Discovery
  • Protein Engineering; Process Sciences
  • Biopharmaceutical Development; Development Analytics and New Technologies:
  • Clinical Assay; Biologics Discovery and Design

It is also designed for professionals who work for the Industry of:

  • Pharmaceuticals,
  • Biologics,
  • Medicine;
  • Clinical Research Organizations;
  • Academic Research Centers;
  • Regulatory Agencies

 


Skip to toolbar